News

The professor of neurology at VCU spoke about the possibility of pairing gene therapies for Huntington disease down the line when they are available.

A planned phase 1/2 trial of the recombinant AAV5 vector treatment is expected to begin dosing patients in the second half of 2019.

The director of the Epilepsy Center at Cleveland Clinic spoke about the use of deep brain stimulation for the treatment of refractory epilepsy, and who the ideal candidate is for implantation.

The director of the Center for Neurodegeneration and Translational Neuroscience and director emeritus, Cleveland Clinic Lou Ruvo Center for Brain Health, spoke about the emerging therapies and biomarkers in Alzheimer disease.

Who knew those animated little fish might do so much more for our patients with neurodevelopmental disorders than provide a calm diversion in the waiting room?

The attending neurologist at Brigham and Women's Hospital spoke about data from an analysis that concluded that women with frontal lobe epilepsy are more likely to experience a worsening of their seizure frequency during pregnancy.

Several network meta-analyses have suggested that ocrelizumab is superior or comparable in its efficacy and safety to the other 14 available disease-modifying therapies in treating relapsing multiple sclerosis.

The director of the MedStar Georgetown University Hospital Headache Center discussed the importance of understanding the biologic mechanisms of migraine for patients and providers.

The pediatric epileptologist at Nicklaus Children’s Hospital discussed the long-term seizure freedom data that looked at the effectiveness of perampanel which demonstrated a gratifying response in seizure control for patients with secondarily generalized seizures.

The neurologist and epileptologist at the Mayo Clinic in Jacksonville spoke about how to best identify adult patients in need of routine EEG and what it will bring to the table relative to the clinician.

The director of the University of Florida’s Tourette Association of America Southeast Regional Center of Excellence spoke about the potential targets for neuromodulation and the progress that has been made with DBS in Tourette.

A recent review of the ICER report on calcitonin gene-related peptide inhibitor monoclonal antibodies has suggested that due to their cost and comparative benefit to available treatments, they should be reserved as second-line treatments.

Neurology News Network for the week of January 19, 2019.

The Director of the Pediatric Epilepsy Center at UCSF Benioff Children's Hospital spoke about what defines a "clinically meaningful change in seizure frequency" using data from a phase 3 clinical trial of ZX008 for the adjunctive treatment of seizures associated with Dravet syndrome.

Uliel-Sibony discussed her and her colleagues' study of CBD, and its findings on when tolerance develops for which patient population.

This is the first biomarker evidence that peripherally administered exenatide may both engage and normalize brain insulin signaling in association with the activation of Akt and mTOR cascades in Parkinson disease.

The executive director of the University of Rhode Island’s George & Anne Ryan Institute for Neuroscience spoke about the phase 1 trial and the years of research that led to it.

The professor and vice chair of the neurology department at UCLA discussed the new VNS, RNS and DBS CPT codes for 2019.

The Clinical Fellow in Neurophysiology and Epilepsy at Massachusetts General Hospital spoke about the implications of this assessment of SUDEP.

The director of Parkinson’s Disease and Movement Disorders Program at Henry Ford Hospital spoke about how improving levodopa delivery systems, among other advancements, has progressed the treatment of the disease.

Having a chronic tic disorder like Tourette syndrome may double the risk of developing cardiometabolic disorders.

The treatment was originally branded as Sabril (Lundbeck) and approved in August 2009 as monotherapy for infantile spasms. This generic formulation approval was granted by the agency to Teva Pharmaceuticals.

The American Headache Society President spoke with NeurologyLive about the recent AHS position statement on the use of migraine treatments in clinical practice

Liu discussed this work and the findings of this proof-of-principle trial in memory in epilepsy.

The NDA was based on the results of 2 pivotal phase 3 clinical studies, SUNRISE 1 and SUNRISE 2, which enrolled approximately 2000 patients, as well as safety studies.

Patients with relapsing multiple sclerosis who are treated sooner rather than later with disease-modifying therapy have a lower risk of converting to secondary progressive disease.

The agency is anticipating upward of 200 INDs per year by 2020 and between 10 and 20 cell and gene therapy approvals per year by 2025.

The associate professor in the department of psychiatry at NYU Langone spoke about the relationship between slow-wave sleep disruption and Alzheimer disease.

A small trial has suggested that patients with myasthenia gravis and dysphagia are not properly assessed by the common clinical scales for these swallowing problems and their risk of silent aspiration.

The direct thrombin inhibitor is planned to be evaluated for its effect on the neurodegenerative disease in a trial of 40 to 60 patients with MCI and Alzheimer, led by researchers at the University of Rhode Island.